Meet the New Standard of Care
The Tandem Mobi system is powered by Control-IQ technology and provides patients with more options for how they manage their diabetes.
Unlike with other AID systems, Tandem users see immediate results on Day 1 after initiation with low rates of hypoglycemia. Control-IQ technology is designed to help increase time in range (70-180 mg/dL) using CGM* values to predict glucose levels 30 minutes ahead and automatically adjust insulin dosing. On average, it exceeds the ADA Standards of Care goal of more than 70% of time spent in range.2
A1c Reduction1
Time in Range3†
Time Below 70 mg/dL3
Note: Studies were conducted using the t:slim X2 insulin pump with Control-IQ technology and Dexcom G6 CGM sensor. Individual symptoms, situations, circumstances, and results may vary.
Tandem Mobi
The only AID system that allows for on-body wear (adhesive sleeve sold separately) with the ability to bolus from the pump if the mobile app is not available. These features contributed to an improved quality of life and overall patient satisfaction.4
Reduction of Burden
according to users who said Tandem Mobi helped reduce the burden of managing diabetes.4
User Satisfaction
according to Tandem Mobi Early Access participants.5
The Tandem Mobi system breaks down the wearability barrier of starting insulin pump therapy by giving patients more discreet and convenient ways to wear their insulin pump with clothing or on-body. This wearability allows them to “forget they were wearing a pump.”6
Tandem SourceReporting Made Simple
Tandem Source is a platform for healthcare professionals to see important diabetes therapy data, access patient reports, and find the tools to help patients manage their diabetes.
Tandem Diabetes Care is the #1 recommended pump brand by endocrinologists and diabetes educators.7 Help your patients choose which Tandem automated insulin delivery system best fits their lifestyle.
How to Prescribe
Ready to prescribe Tandem Mobi? Get the process started by downloading and filling out these three forms. Our referral process includes a free insurance benefits check for your patients.
* CGM sold separately.
† With optimized correction factor "Rule of 1500."
References
Note: Studies were conducted using a t:slim X2 insulin pump with Control-IQ technology and a Dexcom G6 sensor.
1. Beck RW, et al. Diabetes Technol Ther. 2023;25(5):329-342.
2. Diabetes Technology: Standards of Care in Diabetes - 2024. Diabetes Care. 2024;47(Suppl. 1):S126-S144.
3. Messer LH, Breton M. Diabetes Technol Ther. 2023;25(12):877-882.
4. Akturk H, et al. Tandem Mobi System: Tiny Pump, Big Control. The Future of AID. Presentation at 84th Scientific Sessions of the American Diabetes Association; June 21-24, 2024; Orlando, FL.
5. As of Oct. 2024, Data on file, Tandem Diabetes Care.
6. Habif S, Manning M, Leas S, et. al. New Paradigms for Wearability with the Tandem Mobi System. Poster presented at the 84th Scientific Sessions of the American Diabetes Association; June 21-24, 2024; Orlando, FL.
7. #1 ratings come from Seagrove Partners HCP Perspectives (Devices), September 2024 Insulin Delivery section N=269
Important Safety Information
RX ONLY.
Indications for Use
Tandem Mobi system: The Tandem Mobi insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is intended for single patient, home use and requires a prescription. The pump is indicated for use in individuals 6 years of age and greater.
Control-IQ technology: Control-IQ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons 6 years of age and greater. Control-IQ technology is intended for single patient use. Control-IQ technology is indicated for use with NovoLog or Humalog U 100 insulin.
Warning: Control-IQ technology should not be used by anyone under the age of 6 years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.
Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using hydroxyurea. Users of a Tandem insulin pump and Control-IQ technology must use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. If your CGM readings do not match your symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. The Tandem pump and the CGM transmitter and sensor must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.
The Tandem Source platform is intended for use by individuals with diabetes mellitus who use Tandem Diabetes Care insulin pumps, their caregivers, and their healthcare providers in home and clinical settings. The Tandem Source platform supports diabetes management through the display and analysis of information uploaded from Tandem insulin pumps.